Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional scope
1.1.2. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Industry Dynamics, Trends and Scope
2.1. Industry Dynamics
2.1.1. Industry driver analysis
2.1.1.1. Increasing burden of kidney disease
2.1.1.2. Rising prevalence of chronic disorders
2.1.1.3. Technological advancements in kidney disorder management devices
2.1.1.4. Growing shift towards home based products
2.1.2. Industry restraint analysis
2.1.2.1. Product recalls
2.1.3. Industry opportunity analysis
2.1.3.1. Increasing number of clinical trials
2.1.3.2. Expanding healthcare infrastructure
2.1.3.3. Development of wearable kidneys
2.1.4. Industry challenge analysis
2.1.4.1. Shortage of healthcare professionals
2.2. Industry Analysis Tools
2.2.1. Industry Analysis – Porter’s
2.2.1.1. Bargaining power of suppliers
2.2.1.2. Bargaining power of buyers
2.2.1.3. Threat of substitutes
2.2.1.4. Threat of new entrants
2.2.1.5. Competitive rivalry
2.2.2. PESTEL Analysis
2.2.2.1. Political & Legal Landscape
2.2.2.2. Economic and Social Landscape
2.2.2.3. Technological landscape
Chapter 3. Competitive Landscape
3.1. Recent Developments & Impact Analysis, By Key Market Participants
3.2. Company/Competition Categorization
3.2.1. Innovators
3.3. Vendor Landscape
3.3.1. List of key distributors and channel partners
3.3.2. Global Key company market share analysis, 2024
3.3.2.1. Baxter.
3.3.2.1.1. Company overview
3.3.2.1.2. Financial performance
3.3.2.1.3. Product benchmarking
3.3.2.1.4. Strategic initiatives
3.3.2.2. Fresenius Medical Care AG
3.3.2.2.1. Company overview
3.3.2.2.2. Financial performance
3.3.2.2.4. Strategic initiatives
3.3.2.3. Nipro Europe Group Companies
3.3.2.3.1. Company overview
3.3.2.3.2. Financial performance
3.3.2.3.3. Product benchmarking
3.3.2.3.4. Strategic initiatives
3.3.2.4. Vantive
3.3.2.4.1. Company overview
3.3.2.4.2. Financial performance
3.3.2.4.3. Product benchmarking
3.3.2.4.4. Strategic initiatives
3.3.2.5. ProKidney Corp
3.3.2.5.1. Company overview
3.3.2.5.2. Financial performance
3.3.2.5.3. Product benchmarking
3.3.2.5.4. Strategic initiatives
3.3.2.6. Vivance
3.3.2.6.1. Company overview
3.3.2.6.2. Financial performance
3.3.2.6.3. Product benchmarking
3.3.2.6.4. Strategic initiatives
3.3.2.7. Renalyx Health Systems Pvt Ltd,
3.3.2.7.1. Company overview
3.3.2.7.2. Financial performance
3.3.2.7.3. Product benchmarking
3.3.2.7.4. Strategic initiatives
3.3.2.8. Asahi Kasei Medical Co., Ltd.
3.3.2.8.1. Company overview
3.3.2.8.2. Financial performance
3.3.2.8.3. Product benchmarking
3.3.2.8.4. Strategic initiatives
3.3.2.9. Mozarc Medical (Medtronic)
3.3.2.9.1. Company overview
3.3.2.9.2. Financial performance
3.3.2.9.3. Product benchmarking
3.3.2.9.4. Strategic initiatives
3.3.2.10. Pollet Medical Group
3.3.2.10.1. Company overview
3.3.2.10.2. Financial performance
3.3.2.10.3. Product benchmarking
3.3.2.10.4. Strategic initiatives
3.3.2.11. D.Med Healthcare GmbH & Co. KG
3.3.2.11.1. Company overview
3.3.2.11.2. Financial performance
3.3.2.11.3. Product benchmarking
3.3.2.11.4. Strategic initiatives
3.3.2.12. F. Hoffmann-La Roche Ltd
3.3.2.12.1. Company overview
3.3.2.12.2. Financial performance
3.3.2.12.3. Product benchmarking
3.3.2.12.4. Strategic initiatives
3.3.2.13. Dialyfix
3.3.2.13.1. Company overview
3.3.2.13.2. Financial performance
3.3.2.13.3. Product benchmarking
3.3.2.13.4. Strategic initiatives
3.3.2.14. B. Braun SE
3.3.2.14.1. Company overview
3.3.2.14.2. Financial performance
3.3.2.14.3. Product benchmarking
3.3.2.14.4. Strategic initiatives
3.3.2.15. NIKKISO Medical Europe GmbH
3.3.2.15.1. Company overview
3.3.2.15.2. Financial performance
3.3.2.15.3. Product benchmarking
3.3.2.15.4. Strategic initiatives